AU2002364549B2 - Vanilloid receptor ligands and their use in treatments - Google Patents

Vanilloid receptor ligands and their use in treatments Download PDF

Info

Publication number
AU2002364549B2
AU2002364549B2 AU2002364549A AU2002364549A AU2002364549B2 AU 2002364549 B2 AU2002364549 B2 AU 2002364549B2 AU 2002364549 A AU2002364549 A AU 2002364549A AU 2002364549 A AU2002364549 A AU 2002364549A AU 2002364549 B2 AU2002364549 B2 AU 2002364549B2
Authority
AU
Australia
Prior art keywords
alkyl
substituted
haloalkyl
halo
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002364549A
Other languages
English (en)
Other versions
AU2002364549A1 (en
Inventor
Yunxin Y. Bo
Partha P. Chakrabarti
Ning Chen
Elizabeth M. Doherty
Christopher H. Fotsch
Nianhe Han
Michael G. Kelly
Qingyian Liu
Mark Henry Norman
Xianghong Wang
Jiawang Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2002364549A1 publication Critical patent/AU2002364549A1/en
Assigned to AMGEN, INC reassignment AMGEN, INC Amend patent request/document other than specification (104) Assignors: AMGEM, INC.
Priority to AU2007200149A priority Critical patent/AU2007200149A1/en
Application granted granted Critical
Publication of AU2002364549B2 publication Critical patent/AU2002364549B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
AU2002364549A 2001-12-10 2002-12-10 Vanilloid receptor ligands and their use in treatments Ceased AU2002364549B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007200149A AU2007200149A1 (en) 2001-12-10 2007-01-15 Vanilloid receptor ligands and their use in treatments

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US33916101P 2001-12-10 2001-12-10
US60/339,161 2001-12-10
US34473701P 2001-12-21 2001-12-21
US60/344,737 2001-12-21
US38333102P 2002-05-22 2002-05-22
US60/383,331 2002-05-22
US40242202P 2002-08-08 2002-08-08
US60/402,422 2002-08-08
PCT/US2002/039589 WO2003049702A2 (en) 2001-12-10 2002-12-10 Vanilloid receptor ligands and their use in treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007200149A Division AU2007200149A1 (en) 2001-12-10 2007-01-15 Vanilloid receptor ligands and their use in treatments

Publications (2)

Publication Number Publication Date
AU2002364549A1 AU2002364549A1 (en) 2003-06-23
AU2002364549B2 true AU2002364549B2 (en) 2007-11-22

Family

ID=27502596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002364549A Ceased AU2002364549B2 (en) 2001-12-10 2002-12-10 Vanilloid receptor ligands and their use in treatments

Country Status (8)

Country Link
US (5) US7582657B2 (https=)
EP (1) EP1463714A4 (https=)
JP (1) JP2005518371A (https=)
AU (1) AU2002364549B2 (https=)
CA (1) CA2468544A1 (https=)
MX (1) MXPA04005427A (https=)
PL (1) PL373484A1 (https=)
WO (1) WO2003049702A2 (https=)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420644T1 (de) * 2002-02-20 2009-01-15 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
WO2003097586A1 (en) 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
BR0313255A (pt) * 2002-08-08 2005-07-12 Amgen Inc Composto, composição farmacêutica, uso de um composto e métodos de fabricar um medicamento e de preparar um composto
EP1688408A3 (en) * 2002-08-08 2007-08-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
AU2003298567B9 (en) * 2002-08-29 2009-07-23 Temple University - Of The Commonwealth System Of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
NZ540381A (en) 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
CA2509233A1 (en) * 2002-12-13 2004-07-01 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
AU2002953533A0 (en) * 2002-12-24 2003-01-16 Arthron Limited Fc receptor modulating compounds and compositions
US20040192728A1 (en) * 2003-02-03 2004-09-30 Ellen Codd Quinoline-derived amide modulators of vanilloid VR1 receptor
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
CA2531401A1 (en) * 2003-07-10 2005-01-27 Neurogen Corporation Substituted heterocyclic diarylamine analogues
JP2007523875A (ja) * 2003-07-15 2007-08-23 ニューロジェン・コーポレーション バニロイド受容体リガンドとしての置換ピリミジン−４−イルアミン類縁体
CA2531619A1 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
EP1780211A3 (en) * 2003-09-30 2007-06-06 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2004278382B2 (en) * 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005040100A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7553848B2 (en) 2004-01-23 2009-06-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
JP2007522233A (ja) * 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療におけるそれらの使用
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
EP1775283A4 (en) * 2004-07-14 2008-12-10 Japan Tobacco Inc 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1)
KR101042490B1 (ko) 2004-07-15 2011-06-16 니뽄 다바코 산교 가부시키가이샤 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제
FR2874015B1 (fr) 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
CA2580119A1 (en) * 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
MX2007007226A (es) 2004-12-17 2007-08-21 Lilly Co Eli Antagonistas receptores novedosos de hormona concentradora de melanina (mch).
WO2006089311A1 (en) * 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
KR101304981B1 (ko) 2005-03-19 2013-09-06 (주)아모레퍼시픽 바닐로이드 수용체 길항물질로서의 신규 화합물, 이의이성체 또는 이의 약학적으로 허용가능한 염, 및 이를함유하는 약학 조성물
US20060223837A1 (en) * 2005-03-24 2006-10-05 Ellen Codd Biaryl derived amide modulators of vanilloid VR1 receptor
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
JP4754566B2 (ja) 2005-07-22 2011-08-24 持田製薬株式会社 新規なヘテロシクリデンアセトアミド誘導体
JP2009514876A (ja) * 2005-11-03 2009-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼのための化合物および組成物
AU2006316005A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
EP1953151A4 (en) * 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
RU2381225C1 (ru) * 2005-11-24 2010-02-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производное циннамида типа морфолина
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
WO2007076104A1 (en) * 2005-12-23 2007-07-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
CA2632508A1 (en) * 2005-12-28 2008-06-05 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity
US7906508B2 (en) * 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
CA2652484A1 (en) * 2006-05-19 2007-11-29 Eisai R & D Management Co., Ltd. Heterocyclic type cinnamide derivative
DK2035369T3 (da) 2006-07-05 2014-10-06 Fibrotech Therapeutics Pty Ltd Terapeutiske
EP1889830A1 (en) 2006-07-10 2008-02-20 Pharmeste S.r.l. Biarylcarboxyarylamides as vanilloid-1 receptor modulators
EP1889837A1 (en) * 2006-07-10 2008-02-20 Pharmeste S.r.l. VR1 vanilloid receptor antagonists with a iononic substructure
EP2050734A1 (en) 2006-07-13 2009-04-22 Kyowa Hakko Kirin Co., Ltd. Pentadienamide derivative
PL2054411T3 (pl) 2006-07-27 2015-02-27 Amorepacific Corp Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
US8034940B2 (en) 2006-08-09 2011-10-11 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
TW200824687A (en) 2006-08-25 2008-06-16 Abbott Lab Compounds that inhibit TRPV1 and uses thereof
US20080095720A1 (en) * 2006-10-18 2008-04-24 Conopco, Inc., D/B/A Unilever Skin Benefit Compositions with a Vanilloid Receptor Antagonist
EP1939181A1 (en) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
FR2911604B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2911605B1 (fr) 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
PE20081692A1 (es) * 2007-01-24 2008-12-18 Mochida Pharm Co Ltd Nuevo derivado de heterocicliden acetamida
CL2008000582A1 (es) * 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
ITFI20070097A1 (it) * 2007-04-20 2008-10-21 Antonio Guarna Molecole eterocicliche contenenti il nucleo della morfolina loro preparazione ed uso.
WO2008140111A1 (ja) * 2007-05-16 2008-11-20 Eisai R & D Management Co., Ltd. シンナミド誘導体のワンポット製造方法
WO2009001374A2 (en) * 2007-06-25 2008-12-31 Aptuit Laurus Pvt Ltd Preparation of ethyl-3'-[((7-chloro-2-quinolinyl)ethenyl)phenyl]-3-oxopropanoate, a key intermediate for montelukast sodium
WO2009023160A2 (en) * 2007-08-11 2009-02-19 The Uab Research Foundation Novel inhibitors of bacterial sortase enzymes and methods of using the same
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
ES2529648T3 (es) 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
WO2009079692A1 (en) 2007-12-21 2009-07-02 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
US20110207987A1 (en) * 2009-11-02 2011-08-25 Salutaris Medical Devices, Inc. Methods And Devices For Delivering Appropriate Minimally-Invasive Extraocular Radiation
DK2227257T3 (da) 2008-01-07 2013-09-30 Salutaris Medical Devices Inc Anordninger til minimal-invasiv ekstraokular afgivelse af stråling til den posteriore del af øjet
US10022558B1 (en) 2008-01-07 2018-07-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US8608632B1 (en) 2009-07-03 2013-12-17 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye
US8602959B1 (en) 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
US9056201B1 (en) 2008-01-07 2015-06-16 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US9873001B2 (en) 2008-01-07 2018-01-23 Salutaris Medical Devices, Inc. Methods and devices for minimally-invasive delivery of radiation to the eye
US20100317860A1 (en) * 2008-01-28 2010-12-16 Ikuo Kushida Crystalline cinnamide compounds or salts thereof
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US8691855B2 (en) 2008-07-02 2014-04-08 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
JP5421366B2 (ja) 2008-07-21 2014-02-19 オトノミ―，インク． 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP2349263B1 (en) 2008-10-23 2014-04-23 Vertex Pharmaceuticals Inc. Modulators of cystic fibrosis transmembrane conductance regulator
EP2179984A1 (en) 2008-10-27 2010-04-28 Congenia S.r.l. Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition
USD691268S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to eye
USD691267S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to eye
USD691270S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to an eye
USD691269S1 (en) 2009-01-07 2013-10-08 Salutaris Medical Devices, Inc. Fixed-shape cannula for posterior delivery of radiation to an eye
TWI402250B (zh) * 2009-02-03 2013-07-21 Nippon Soda Co Phenolic compounds and recording materials
WO2010089982A1 (ja) * 2009-02-03 2010-08-12 日本曹達株式会社 リライタブル記録材料
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
EP2491030B1 (en) 2009-10-22 2015-07-15 Fibrotech Therapeutics PTY LTD Fused ring analogues of anti-fibrotic agents
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011308256B2 (en) * 2010-09-28 2015-08-20 Daewoong Pharmaceutical Co., Ltd. Novel method of preparing benzoimidazole derivatives
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
US20150225369A1 (en) * 2012-08-29 2015-08-13 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
HK1214587A1 (en) 2012-12-28 2016-07-29 Nippon Zoki Pharmaceutical Co., Ltd. Cinnamamide derivative
FR3006192A1 (fr) * 2013-05-30 2014-12-05 Centre Nat Rech Scient Composes de type phenyle propenamide pour leur utilisation en tant que medicament
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
WO2016077240A2 (en) 2014-11-10 2016-05-19 Forge Life Science, Llc Anti-hcmv compositions and methods
JP2018512436A (ja) * 2015-04-15 2018-05-17 バレント・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＶａｌｅｎｔ ＢｉｏＳｃｉｅｎｃｅｓ ＬＬＣ （ｓ）−２’−ビニル−アブシジン酸誘導体
KR102439852B1 (ko) * 2015-04-17 2022-09-05 가천대학교 산학협력단 2-아미노퀴놀린-8-올 유도체, 및 이의 용도
KR101806485B1 (ko) 2015-09-04 2017-12-08 서울대학교산학협력단 파이퍼 아마이드 유도체를 포함하는 피부 미백용 조성물
CN105130964A (zh) * 2015-09-28 2015-12-09 侯方杰 一种可用于制备治疗心血管疾病药物的化合物及其制备方法、用途
CN105153125A (zh) * 2015-09-29 2015-12-16 青岛友诚高新技术有限公司 一种可用于制备保护心肌缺血药物的化合物及其制备方法、用途
CN105085492A (zh) * 2015-09-29 2015-11-25 青岛友诚高新技术有限公司 一种可用于制备治疗冠状动脉粥样硬化药物的化合物及其制备方法、用途
CN105130965A (zh) * 2015-10-08 2015-12-09 侯方杰 一种可用于制备治疗心血管疾病药物的化合物及其制备方法、用途
CN105461700A (zh) * 2015-12-02 2016-04-06 青岛市中心医院 一种可用于制备抗乳腺癌药物的化合物及其制备方法、用途
WO2017102014A1 (en) * 2015-12-17 2017-06-22 Universite D'aix-Marseille Propenamide thiophene derivatives as flavivirus inhibitors and their use
USD814638S1 (en) 2016-05-11 2018-04-03 Salutaris Medical Devices, Inc. Brachytherapy device
USD814637S1 (en) 2016-05-11 2018-04-03 Salutaris Medical Devices, Inc. Brachytherapy device
USD815285S1 (en) 2016-05-11 2018-04-10 Salutaris Medical Devices, Inc. Brachytherapy device
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
USD808528S1 (en) 2016-08-31 2018-01-23 Salutaris Medical Devices, Inc. Holder for a brachytherapy device
USD808529S1 (en) 2016-08-31 2018-01-23 Salutaris Medical Devices, Inc. Holder for a brachytherapy device
WO2018101793A2 (ko) * 2016-12-01 2018-06-07 서울대학교 산학협력단 아미드 유도체 화합물, 이의 입체이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 포함하는 피부 노화 억제, 주름 개선, 또는 피부 상처 치료용 약학적 또는 화장료 조성물
ES2901617T3 (es) * 2016-12-14 2022-03-23 Glaxosmithkline Ip Dev Ltd Bisarilamidas como reguladores de NRF2
CA3052036A1 (en) 2017-02-03 2018-08-09 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
WO2019084338A1 (en) 2017-10-25 2019-05-02 University Of South Florida DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
KR102334947B1 (ko) * 2020-04-22 2021-12-06 주식회사 제이맥켐 Trpv1 길항제로서 벤즈이미다졸론계 시남아마이드 유도체 및 이를 유효성분으로 함유하는 통증의 치료 또는 예방용 약학적 조성물
CN113549018B (zh) * 2020-04-24 2024-02-27 中国药科大学 蛋白激酶抑制剂及其衍生物，制备方法、药物组合物和应用
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
WO2024206284A2 (en) * 2023-03-27 2024-10-03 Rutgers, The State University Of New Jersey Therapeutic compounds
CN120398870A (zh) * 2024-01-31 2025-08-01 深圳晶蛋生物医药科技有限公司 一种苯并吗啉类化合物及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853561A (en) * 1970-11-26 1974-12-10 Hoechst Ag Process for the preparation of screen printing stencils using intermediate support for light sensitive layer
US3940422A (en) * 1973-01-18 1976-02-24 Kissei Yakuhin Kogyo Kabushiki Kaisha Aromatic carboxylic amide derivatives
JPS63154663A (ja) * 1986-12-17 1988-06-27 Kanegafuchi Chem Ind Co Ltd ３，５−ジ−タ−シヤリ−ブチル−４−ヒドロキシケイ皮酸アミド誘導体
US4753934A (en) * 1983-02-28 1988-06-28 Celamerck Gmbh & Co. Kg Acrylic acid heterocyclic amides, fungicidal compositions and use
US5780487A (en) * 1995-08-07 1998-07-14 Amer Moh Samir S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide
US5969140A (en) * 1995-06-15 1999-10-19 Tanabe Seiyaku Co., Ltd. Naphthalene derivatives, process for the preparation thereof, and intermediates therefor
WO2002006237A1 (en) * 2000-07-18 2002-01-24 Yamanouchi Pharmaceutical Co., Ltd. Medicine comprising dicyanopyridine derivative
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US456346A (en) * 1891-07-21 Henry e
US87922A (en) * 1869-03-16 Improvement in gas-burners
US4011236A (en) 1968-09-09 1977-03-08 Merck & Co., Inc. N-(benzimidazol-2-yl)arylcarboxamides as ultraviolet (uv) light absorbers
FR2230764B1 (https=) * 1973-05-21 1977-02-11 Verdol Sa
US4536346A (en) 1983-05-06 1985-08-20 American Cyanamid Company Aralkanamidophenyl compounds
FR2559763B1 (fr) 1984-02-22 1986-07-11 Centre Nat Rech Scient Composes possedant, notamment, des proprietes inhibitrices vis-a-vis de la lignification dans les vegetaux et procede pour la reduction de leur taux de lignine
JPH064584B2 (ja) 1984-02-29 1994-01-19 沢井製薬株式会社 新規アニリド誘導体
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
US4927838A (en) 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
DE3803775A1 (de) 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh Neue substituierte lactame, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4908381A (en) 1988-12-05 1990-03-13 Ecolab Inc. Antimicrobial film-forming compositions
US5143919A (en) 1990-08-17 1992-09-01 Takeda Chemical Industries, Ltd. Thienopyridine derivatives and their pharmaceutical use
DE69216873T2 (de) 1991-02-21 1997-08-21 Sankyo Co Benzolderivate zum Fördern der Produktion des Nervenwachstumsfaktors
GB9208492D0 (en) 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
US5453421A (en) 1992-09-11 1995-09-26 E. R. Squibb & Sons, Inc. Aryl and heterocyclic substituted propenamide derivatives
JPH06179660A (ja) 1992-10-14 1994-06-28 Nippon Soda Co Ltd ジシアノピラジン誘導体
US5731324A (en) 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
GB9319243D0 (en) 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds
GB9504361D0 (en) 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
AU2652397A (en) 1996-05-13 1997-12-05 Nippon Shinyaku Co. Ltd. Substituted ethylene compounds and drugs
US5776930A (en) 1996-06-28 1998-07-07 Merck & Company, Inc. Pharmaceutical preparation
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
NZ507032A (en) 1998-03-19 2003-06-30 Pharmacia & Upjohn 1,3,4-thiadiazoles useful for the treatment of herpes and cytomegalovirus infections
CA2338804A1 (en) 1998-07-28 2000-02-10 Smithkline Beecham Corporation Propenamides as ccr5 modulators
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
AU1707700A (en) 1998-10-29 2000-05-22 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
DE19935219A1 (de) 1999-07-27 2001-02-01 Boehringer Ingelheim Pharma Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
EP1218336A2 (en) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
EP1268484A1 (en) 2000-03-17 2003-01-02 Novo Nordisk A/S Condensed imidazoles as histamine h3 receptor ligands
GB0014022D0 (en) * 2000-06-08 2000-08-02 Novartis Ag Organic compounds
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853561A (en) * 1970-11-26 1974-12-10 Hoechst Ag Process for the preparation of screen printing stencils using intermediate support for light sensitive layer
US3940422A (en) * 1973-01-18 1976-02-24 Kissei Yakuhin Kogyo Kabushiki Kaisha Aromatic carboxylic amide derivatives
US4753934A (en) * 1983-02-28 1988-06-28 Celamerck Gmbh & Co. Kg Acrylic acid heterocyclic amides, fungicidal compositions and use
JPS63154663A (ja) * 1986-12-17 1988-06-27 Kanegafuchi Chem Ind Co Ltd ３，５−ジ−タ−シヤリ−ブチル−４−ヒドロキシケイ皮酸アミド誘導体
US5969140A (en) * 1995-06-15 1999-10-19 Tanabe Seiyaku Co., Ltd. Naphthalene derivatives, process for the preparation thereof, and intermediates therefor
US5780487A (en) * 1995-08-07 1998-07-14 Amer Moh Samir S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide
WO2002006237A1 (en) * 2000-07-18 2002-01-24 Yamanouchi Pharmaceutical Co., Ltd. Medicine comprising dicyanopyridine derivative
WO2002079197A1 (en) * 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Bansal, European Journal of Medicinal Chemistry, 36(1), 2001, 81-92 *
CA 90: 137633 *
CA 93: 46364 *
CA 95: 150360 *
Kibble, I Drugs, 4(12) 2001 1319-1323 *
Kreutzberger, J. Heterocyclic chemistry, 12, 1975, 665-667 *
Pau, Il Farmaco, 53, 1998, 233-240 *
Peng, JACS, 78, 1956, 3703-3708 *
Rajan, Bioorganic & Medicinal Chemistry Letters, 11(2) 2001 215-217 *
RN 122097-88-5 *
RN 166046-65-7 *
RN 19933-09-6 *
Saraf, Pharmaceutical Chemistry Journal, 26(7/8) 1992 598-602 *
Yeung, J. Med. Chem. 25, 1982, 191-195 *

Also Published As

Publication number Publication date
EP1463714A2 (en) 2004-10-06
US7579347B2 (en) 2009-08-25
WO2003049702A2 (en) 2003-06-19
US20050227986A1 (en) 2005-10-13
PL373484A1 (en) 2005-09-05
CA2468544A1 (en) 2003-06-19
WO2003049702A8 (en) 2004-08-19
MXPA04005427A (es) 2005-04-19
US20030195201A1 (en) 2003-10-16
JP2005518371A (ja) 2005-06-23
US20060030618A1 (en) 2006-02-09
AU2002364549A1 (en) 2003-06-23
US20050272931A1 (en) 2005-12-08
EP1463714A4 (en) 2005-10-19
US20090264424A1 (en) 2009-10-22
WO2003049702A3 (en) 2004-02-12
US7582657B2 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
AU2002364549B2 (en) Vanilloid receptor ligands and their use in treatments
US7396831B2 (en) Vanilloid receptor ligands and their use in treatments
US7390907B2 (en) Vanilloid receptor ligands and their use in treatments
JP2007522235A (ja) バニロイド受容体リガンドとしての使用のためのピリミジン誘導体及び疼痛の治療におけるそれらの使用
JP2007522233A (ja) バニロイド受容体リガンド及び治療におけるそれらの使用
WO2012177896A1 (en) Trpm8 antagonists and their use in treatments
US7314933B2 (en) Vanilloid receptor ligands and their use in treatments
AU2007200149A1 (en) Vanilloid receptor ligands and their use in treatments
EP1780196A2 (en) Pyridine derivatives for use as vanilloid receptor ligands
EP1780211A2 (en) Vanilloid receptor ligands and their use in treatments

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT FROM AMGEM, INC. TO AMGEN, INC

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired